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SARS-CoV-2 infection in beta thalassemia: Preliminary data
from the Italian experience
To the Editor:
Patients with pre-existent chronic morbidities are likely to be more
severely affected by SARS-Cov2 infection, but no data are available
regarding Thalassemic Syndromes (TS). Note, TS and hemoglobin vari-
ants represent, according to WHO, one of the most frequent causes
of anemia, affecting more than 7% of the world population.1 Thalasse-
mic Syndromes are classified in either transfusion-dependent thalas-
semia (TDT) or non-transfusion-dependent thalassemia (NTDT).
Infectious complications, mainly from bacteria, constitute a common
cause of mortality and morbidity in TS. Stress erythropoiesis, iron
overload, splenectomy and adrenal insufficiency among others may
contribute to increase susceptibility to infection.2
To verify the impact of SARS-CoV-2 infection on TS, we set-up a
specific survey by electronic Case Report Form (eCRF).3 Inclusion
criteria require at least 15 days of follow-up from either the onset of
symptoms or SARS-CoV2 positivity. The survey was approved by
Ethics Committee and eCRF was shared with the Centers of Italian
Hemoglobinopathies Network. The “Società Italiana Talassemie ed
Emoglobinopatie” (SITE), has estimated the presence in Italy of
approximately 5000 TDT and 1900 NTDT patients.3
As of 10 April 2020, 11 cases of TS and COVID-19 have been
collected (see supplementary information). All the reported patients
are in Northern Italy, where the rate of infection is higher, reflecting
the national epidemiology.
The mean age is 44 ± 11 years (range 31-61 years) and 55%
(6/11) are females. Ten patients are TDT, and one is NTDT. All the
patients have thalassemia associated comorbidities, eight are
splenectomized, and one patient (#9 in the supplementary table) has
pulmonary hypertension treated with sildenafil. The likely source of
infection has been detected in 55% (6/11) of cases: two had contacts
with COVID-19 positive subjects, and four had occupational exposure
(three are nurses working in hospital or assisted living facilities).
Three patients were asymptomatic. One patient (#3 in supple-
mentary information) was admitted for high fever and bone marrow
hypoplasia, lymphopenia, and agranulocytosis (on treatment with def-
eriprone) and tested positive at the third swab. Six out of 11 were
hospitalized, but no one required mechanical ventilation. The patient
with more severe symptoms who required more intensive ventilation
support with continuous positive airway pressure (CPAP) has a history
of diffuse large B-cell lymphoma, treated with chemotherapy in the
previous year, currently in complete remission. Of the six people
admitted to the hospital, only three received supposedly specific
treatment for COVID-19: one hydroxychloroquine (HCQ), one HCQ
plus ritonavir/darunavir, and one HCQ plus anakinra. Patient #3 did
not receive HCQ due to concomitant therapy with amiodarone and an
increased risk of life-threatening arrhythmia. The clinical course ranged
from 10 to 29 days. Ten patients have clinically recovered and are on
a daily remote phone call follow-up. Splenectomy which was present
in 8/11 patients did not seem to affect the clinical course. Of note,
except for the patient with myelosuppression, no increase in blood
requirement was observed. When luspatercept treatment was halted
in the NTDT patient, hemoglobin fell from 110 to 82 g/L, a value simi-
lar to the pre-luspatercept period. Neither death nor severe SARS or
signs of cytokines storm were observed in these 11 subjects, which
may be surprising, taking into account the mean age and the presence
of severe comorbidities.
Our data, although preliminary, do not indicate increased severity
of COVID-19 in TS. A larger number of cases needs to be collected to
define the impact of this new infection and its outcome in these frag-
ile patients.
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SUPPORTING INFORMATION
Additional supporting information may be found online in the
Supporting Information section at the end of this article.
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